Topic: Pay for delay

Takeda and Endo hit with pay-for-delay claims

Takeda Pharmaceutical and Endo International are facing a lawsuit over an alleged scheme to block generic competition to Takeda’s branded anti-constipation drug Amitiza.

28 June 2021

Health authorities should have pushed alternative medication, Servier tells UK court

Servier has kicked off its bid to convince a UK court that national health authorities should have encouraged doctors to prescribe cheaper generic drugs to mitigate their losses from its pay-for-delay settlements relating to a blood pressure medication.

17 June 2021

Quarantine hampers in-person evidence plans in Servier damages claim

A senior official at Servier may have to give evidence via videolink at a preliminary issues trial next week due to coronavirus restrictions, as the drugmaker seeks to prove that national health authorities in the UK should have mitigated any losses resulting from its alleged anticompetitive conduct.

09 June 2021

CAT upholds pay-for-delay decision but trims penalties

The UK’s specialist competition tribunal has confirmed that GlaxoSmithKline and three generic drugmakers broke competition rules by entering into pay-for-delay agreements for the antidepressant drug paroxetine – but slashed the original fines by £27 million.

10 May 2021

Fifth Circuit upholds FTC’s Impax decision

There is substantial evidence to support the Federal Trade Commission’s conclusion that a pay-for-delay settlement between Endo Pharmaceuticals and Impax Laboratories violated federal antitrust law, the US Court of Appeals for the Fifth Circuit has ruled.

14 April 2021

First EU pay-for-delay fines survive ECJ challenge

In a highly-anticipated ruling, the European Court of Justice has confirmed the European Commission’s first-ever pay-for-delay decision fining Lundbeck and five generic drugmakers a combined €146 million.

25 March 2021

Scott Morton backs Biden administration to tackle exclusionary conduct in drugs markets

Challenging pharmaceutical companies’ exclusionary conduct is a “low-hanging fruit” that could help the Biden administration lower the cost of drugs in the US, a former Department of Justice official has said.

12 March 2021

State court dismisses Mississippi’s pay-for-delay claims against Teva

The State of Mississippi has failed to demonstrate that a state court has jurisdiction over claims that Teva Pharmaceuticals entered into an anticompetitive reverse-payment settlement, a local judge has ruled.

11 February 2021

FTC challenges second settlement between Endo and Impax

Endo Pharmaceuticals abandoned its plans to re-enter the market for an opioid painkiller after concluding it would be more profitable to split monopoly profits with Impax Laboratories, the Federal Trade Commission has alleged.

29 January 2021

Get unlimited access to all Global Competition Review content